Cardoza-Ochoa et al. calculated via specific software the total lesion prostate-specific membrane antigen (wbTl-PSMA) and whole-body PSMA-derived tumor volume (wbPSMA-TV) of each metastatic foci on 18F-PSMA-1007 PET/CT in 110 patients with biochemically recurrent prostate cancer. This evidence concerns the gene FOLH1 and neoplasm.